Rachel E.Page


Chicago + 1.312.269.4092

Rachel Page focuses her practice on the representation of health care and life sciences companies. She represents hospitals, health systems, managed care organizations, physician group practices, pharmaceutical and medical device manufacturers, and emerging and established companies in the digital health sector.

Rachel counsels clients on regulatory and compliance issues, including federal and state anti-kickback statutes, Medicare and Medicaid reimbursement, the Physician Payments Sunshine Act (Open Payments), compliance program development and assessment, clinical research and U.S. Food & Drug Administration (FDA) regulations, licensure, direct-to-consumer telemedicine, and state corporate practice of medicine doctrines. She also defends health care and life sciences clients in investigations and litigation relating to the False Claims Act, the federal Anti-Kickback Statute, and the Stark Law brought by federal agencies and qui tam whistleblowers.

Her experience also includes advising clients engaged in strategic transactions, including hospital, hospice, home health, and physician practice acquisitions; private equity investments; and corporate and commercial arrangements in the life sciences industry.

Prior to attending law school, Rachel worked in the legal and compliance department for a regional health insurance company during the implementation of the Affordable Care Act. She is a member of the American Health Lawyers Association and the Illinois Association of Healthcare Attorneys.


  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • AbbVie acquires Mitokinin, Inc.Jones Day advised AbbVie Inc. in its exclusive right to acquire Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
  • Digital health companies, specialty hospitals, and health systems maintain compliance with multistate requirements through 50-state surveyJones Day is representing digital health companies, specialty hospitals, and health systems in maintaining compliance with multistate requirements through a regularly updated, extensive 50-state survey on state laws and regulations applicable to telehealth activities of physicians and other health care professionals including licensing, establishing patient relationships, provider-to-provider consulting, supervision and delegation among providers, and prescribing and treatment standards.
  • ProMedica Health System acquires Toledo Orthopaedic SurgeonsJones Day advised ProMedica Central Physicians, an affiliate of ProMedica Health System, Inc., in its acquisition of Toledo Orthopaedic Surgeons, an orthopedic surgery and sports medicine practice, and employment of its physicians.
  • Riverside portfolio company acquires CordicoJones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company Lexipol, LLC of Cordico, a provider of purpose-built, mobile health and wellness applications that deliver high-quality wellness tools, resources and assessments to public safety customers including law enforcement, fire, EMS, corrections, and more.
  • STERIS acquires Key Surgical for approximately $850 millionJones Day advised STERIS plc (NYSE: STE) in the $850 million acquisition of Key Surgical, a leading global provider of sterile processing, operating room, and endoscopy products, and a portfolio company of Water Street Healthcare Partners, LLC.
  • Telehealth provider obtains dismissal of complaint before state regulatory boardJones Day represented a telehealth provider in responding to a complaint filed with a state regulatory board.
  • PolyOne acquires Clariant color and additive masterbatch business for $1.5 billionJones Day advised PolyOne Corporation in the $1.5 billion purchase of Clariant’s global color and additive masterbatch business.
  • Integrated Medical Professionals sold to Lee Equity PartnersJones Day advised Integrated Medical Professionals, PLLC, a multi-specialty physician group specializing in urology, radiation oncology, and pathology, in its acquisition by Lee Equity Partners.
  • Digital health company expands telehealth programming in response to the COVID-19 public health crisisJones Day represented a digital health company in the expansion of their telehealth programming in response to the COVID-19 public health crisis.
  • Concord Health Partners participates in $25 million investment in Pieces TechnologiesJones Day represented Concord Health Partners LLC in connection with their investment in Pieces Technologies, a healthcare artificial intelligence and technology company that connects health systems and the community to address clinical and social determinants of health.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Imaging provider negotiates favorable settlementJones Day represented a national diagnostic imaging services provider in connection with a False Claims Act qui tam case alleging that the provider's sales and marketing practices were in violation of the federal Anti-Kickback Statute.
  • Zitelli & Brodland sells non-clinical assets to QualDermJones Day advised Zitelli & Brodland, PC in the sale of substantially all non-clinical assets to QualDerm Partners, a private equity backed dermatology practice management company.
  • Gryphon Investors acquires majority interest in Water’s Edge DermatologyJones Day represented Gryphon Investors, Inc. as its regulatory counsel in connection with its acquisition of a majority interest in Water’s Edge Dermatology, a leading provider of comprehensive dermatology services in Florida.
  • Total, NOVA, Borealis form venture for U.S. Gulf Coast projectsJones Day advised Total Petrochemicals & Refining USA, and affiliates of Austria’s Borealis AG and Canada’s NOVA Chemicals (both affiliates of the UAE’s Mubadala Investment Company) in the formation of a joint venture to build a $1.7 billion, 1 million ton per year ethane cracker in Port Arthur, Texas, acquisition of Total’s existing 400,000 ton per year two-line polyethylene plant in Bayport, Texas, and building of a new 625,000 ton per year Borstar PE plant at the Bayport site.
  • Emerging digital health company launches multi-state telehealth platformJones Day advised an emerging digital health company in launching its telehealth operations in multiple states throughout the U.S., with additional expansion to come.